Innovative Cellular Therapeutics (ICT) is a Rockville, MD-based, clinical stage, solid tumor CAR-T focused biotech company with a Shanghai-based R&D engine to optimize its programs for the US market, which is ICT’s sole focus. ICT already has a US FDA-cleared liquid tumor CAR-T IND (92% ORR with 54% CR in IRB-approved human trials in NHL, incl. PD-L1 positive patients, in China), and is in pre-IND discussions to move its two leading solid tumor CAR-T programs in colorectal and thyroid cancer into the clinic in the US starting first part of 2021. 60% ORR with 20% CR has been observed across colorectal and thyroid cancer patients treated with ICT’s proprietary CoupledCAR solid tumor CAR-T platform technology in IRB-approved human trials in multiple hospital sites in China. ICT’s cell manufacturing process is approximately twice as fast as classic CAR-T and TCR-T, and approximately three times as fast as TIL. This shortened process is also a significant cost saver for ICT’s CoupledCAR vs these other cell therapies.